Bravecto For Medium Dogs 22- 44 Lbs (Green) 2 Chews

What is Arthrimed Tablets Bravecto For Medium Dogs 22- 44 Lbs (Green) 2 Chews?

Arthrimed Tablets Bravecto For Medium Dogs 22- 44 Lbs (Green) 2 Chews is a prescription-strength, chewable tablet designed to kill fleas and ticks in medium-sized dogs. Each green chew is formulated for dogs weighing between 22 and 44 pounds and provides up to 12 weeks of continuous protection. Marketed under the Arthrimed Tablets brand and sold by BestVetCare, this product is an alternative to monthly topical treatments, offering a convenient oral solution for pet owners focused on long-term parasite prevention.

Key features

• Extended Protection — One chew delivers up to 12 weeks of flea and tick control.
• Targeted Dosage — Specifically formulated for dogs 22-44 lbs; green chews for easy identification.
• Fast-Acting Formula — Begins killing fleas within 2 hours and ticks within 12 hours.
• Oral Administration — Palatable chews eliminate the mess of topical treatments.
• Vet-Recommended — Contains the active ingredient fluralaner, trusted by veterinarians.
• Convenient Packaging — Sold as a pack of 2 chews for back-to-back dosing every 3 months.
• Available Online — Sold through BestVetCare with options for auto-order and coupon discounts.

Who is Arthrimed Tablets Bravecto For Medium Dogs 22- 44 Lbs (Green) 2 Chews for?

This product is ideal for owners of medium-sized dogs who want a long-lasting, easy-to-administer flea and tick solution. It’s especially beneficial for pets in high-parasite environments or those with sensitivities to topical treatments. Veterinarians often recommend it for dogs needing consistent protection without monthly reminders. It requires a prescription, so it's best suited for pet owners who work closely with their vet on preventive care.

How does Arthrimed Tablets Bravecto For Medium Dogs 22- 44 Lbs (Green) 2 Chews compare?

Compared to monthly topical treatments, Bravecto offers longer protection with fewer doses, reducing the risk of missed applications. Unlike standard polypropylene-based collars or short-acting oral chews, Bravecto’s 12-week efficacy stands out. It’s comparable to other systemic oral treatments but differs from fixed-dose generics by offering precise weight-based formulations. While more expensive upfront than some monthly options, its extended duration can reduce long-term costs and improve compliance.